Antibiotic Treatment of Recurrent Episodes of Asthma in Children

Conditions

Childhood Asthma With Acute Exacerbation

Keywords

wheeze, infections

Brief summary

Copsac has discovered that asthmatic exacerbations are as closely linked to bacterial as to viral infection. The current study will examine whether treatment of asthmatic exacerbations with macrolide antibiotics - in the abscence of clear clinical bacterial infection which would in any case precipitate antibiotic treatment - has an effect on either the particular episode, or subsequently. Macrolide antibiotics are chosen for ease of administration ensuring high compliance, antibiotic appropriacy, and anti-inflammatory properties.

Parisa Mohammadzadeh, Julie B. Rosenberg, Rebecca Vinding, Jens Richardt Møllegaard Jepsen, Ulrich Lindberg et al. (20 authors)

BMJ Open2022-02-0117 citations

10.1136/bmjopen-2020-047706

The Airway Microbiota Modulates Effect of Azithromycin Treatment for Episodes of Recurrent Asthma-like Symptoms in Preschool Children: A Randomized Clinical Trial

Jonathan Thorsen, Jakob Stokholm, Morten Arendt Rasmussen, Martin Steen Mortensen, Asker Brejnrod et al. (11 authors)

American Journal of Respiratory and Critical Care Medicine2021-03-1748 citations

10.1164/rccm.202008-3226oc

Prenatal vitamin D supplementation reduces risk of asthma/recurrent wheeze in early childhood: A combined analysis of two randomized controlled trials.

Wolsk HM, Chawes BL, Litonjua AA, Hollis BW, Waage J, Stokholm J, Bønnelykke K, Bisgaard H, Weiss ST.

2017-10-27132 citations

10.1371/journal.pone.0186657

Azithromycin for episodes with asthma-like symptoms in young children aged 1-3 years: a randomised, double-blind, placebo-controlled trial.

Stokholm J, Chawes BL, Vissing NH, Bjarnadóttir E, Pedersen TM, Vinding RK, Schoos AM, Wolsk HM, Thorsteinsdóttir S, Hallas HW, Arianto L, Schjørring S, Krogfelt KA, Fischer TK, Pipper CB, Bønnelykke K, Bisgaard H.

2015-12-17118 citations

10.1016/s2213-2600(15)00500-7

Interventions

DRUGAzithromycin

10 mg/kg peroral for 3 consecutive days

OTHERPlacebo mixture

Placebo mixture containing no active substance.

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

1 Years to 3 Years

Healthy volunteers

No

Inclusion criteria

* Participation in the COPSAC2010 cohort * recurrent wheeze * and others

Exclusion criteria

* Macrolide allergy * Heart, liver or kidney disease. * and others

Design outcomes

Primary

Measure	Time frame
Symptom scoring	1 to 3 years of age
Duration in days of each asthmatic episode from randomisation start	1 to 3 years of age

Secondary

Measure	Time frame
need for PO steroids during the episode	1 to 3 years of age
beta-agonist use during the asthmatic episode	1 to 3 years of age
time lapse until the next asthmatic episode	1 to 3 years of age
MD assessment of the episode	1 to 3 years of age
Family's assessment of the episode	1 to 3 years of age
Asthma related health and economic assessment	1 to 3 years of age
percentage of time away from kindergarten or, for the parents, away from work	1 to 3 years of age
stratification of the above parameters according to bacterial colonisation of the airways	1 to 3 years of age

Countries

Denmark

Contacts

PRINCIPAL_INVESTIGATORKlaus Bønnelykke, MD, PhD

Copenhagen Studies on Asthma in Childhood

Outcome results

None listed